mdl-62873 and teicoplanin-aglycone

mdl-62873 has been researched along with teicoplanin-aglycone* in 1 studies

Other Studies

1 other study(ies) available for mdl-62873 and teicoplanin-aglycone

Article	Year
In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile. Antimicrobial agents and chemotherapy, 1991, Volume: 35, Issue:1 Seventy strains of Clostridium difficile, all isolated from symptomatic patients, were found to be uniformly susceptible to ramoplanin, a new glycolipodepsipeptide antibiotic, and to four glycopeptides (vancomycin, teicoplanin, and two semisynthetic teicoplanin derivatives). Ramoplanin is recommended for further evaluation in the treatment of C. difficile-associated disease. Topics: Anti-Bacterial Agents; Clostridioides difficile; Depsipeptides; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Glycopeptides; Humans; Microbial Sensitivity Tests; Peptides, Cyclic; Ristocetin; Teicoplanin; Vancomycin	1991

Article

Year

In vitro activities of ramoplanin and four glycopeptide antibiotics against clinical isolates of Clostridium difficile.

Antimicrobial agents and chemotherapy, 1991, Volume: 35, Issue:1

Seventy strains of Clostridium difficile, all isolated from symptomatic patients, were found to be uniformly susceptible to ramoplanin, a new glycolipodepsipeptide antibiotic, and to four glycopeptides (vancomycin, teicoplanin, and two semisynthetic teicoplanin derivatives). Ramoplanin is recommended for further evaluation in the treatment of C. difficile-associated disease.

Topics: Anti-Bacterial Agents; Clostridioides difficile; Depsipeptides; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Glycopeptides; Humans; Microbial Sensitivity Tests; Peptides, Cyclic; Ristocetin; Teicoplanin; Vancomycin

1991